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Abstract: Serological thymidine kinase 1 (STK1) is a reliable proliferation marker for 
prognosis, monitoring tumour therapy, and relapse. Here we investigated the use of STK1 
OPEN ACCESS Sensors 2011, 11  11065 
 
 
in  health  screening  for  early  detection  of  pre-malignant  and  malignant  diseases.  The 
investigation was based on 35,365 participants in four independent health screening studies 
in China between 2005–2011. All participants were clinically examined. The concentration 
of  STK1  was  determined  by  a  sensitive  chemiluminescent  dot  blot  ECL  assay.  The 
ROCvalue of the STK1 assay was 0.96. At a cut-off STK1 value of 2.0 pM, the likelihood 
(+) value was 236.5, and the sensitivity and the specificity were 0.78 and 0.99, respectively. 
The  relative  number  of  city-dwelling  people  with  elevated  STK1  values  (≥2.0  pM)  
was 0.8% (198/26,484), while the corresponding value for the group of oil-field workers 
was  5.8%  (514/8,355).  The  latter  group  expressed  significantly  higher  frequency  of 
refractory anaemia, fatty liver, and obesity, compared to the city dwellers, but no cases of 
breast hyperplasia or prostate hyperplasia. Furthermore, people working in oil drilling/oil 
transportation showed higher STK1 values and higher frequency of pre-malignancies and 
benign diseases than people working in the oil-field administration. In the STK1 elevated 
group  of the  city-dwelling people, a  statistically significantly higher number of  people 
were found to have malignancies, pre-malignancies of all types, moderate/severe type of 
hyperplasia of breast or prostate, or refractory anaemia, or to be at high risk for hepatitis B, 
compared to people with normal STK1 values (<2.0 pM). No malignancies were found in 
the normal STK1 group. In the elevated STK1 group 85.4% showed diseases linked to a 
higher risk for pre-/early cancerous progression, compared to 52.4% of those with normal 
STK1  values.  Among  participants  with  elevated  STK1  values,  8.8%  developed  new 
malignancies or progress in their pre-malignancies within 5 to 72 months, compared to 0.2% 
among people with normal STK1 values. People who showed elevated STK1 values were 
at about three to five times higher risk to develop malignancies compared to a calculated 
risk based on a cancer incidence rate of 0.2–0.3%. We conclude that serological TK1 protein 
concentration is a reliable marker for risk assessment of pre/early cancerous progression. 
Keywords: thymidine kinase 1; health screening; pre-malignancy; malignancy; biomarker; 
tumour marker 
 
1. Introduction 
Cancer is a leading cause of death in China, and the number of affected individuals is increasing, 
although different methods of treatment for cancer, for example, surgery, radiotherapy, chemotherapy, 
and endocrine therapy have been improved tremendously in recent decades. These factors, along with 
the information that about 98% of health-screened people show diseases or illness, some of them 
linked to development of pre-malignancies and malignancies [1-3], indicate that health screening is an 
important part of improving the quality of life. 
Cancer can be treated effectively, if discovered at an early stage. Non-invasive serological methods 
for  early  detection  of  tumours  may  reveal  potential  malignancies  before  assessment  by  imaging 
techniques is possible, and thus increase the possibility of curing patients.  Although a number of 
tumour markers have been identified [4-6], a review of the literature shows that measurements of most Sensors 2011, 11  11066 
 
 
tumour  markers  alone  are  often  insufficient  to  diagnose  malignancies  in  health  screening  [3]. 
Guidelines for the use of tumour markers in a range of malignancies have been set up and published by 
the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), the (U.S.) 
National Cancer Institute (NCI), and the (U.S.) National Comprehensive Cancer Network (NCCN). 
Pre-malignancies  are  easier  to  cure  than  malignancies.  Detecting  pre-malignancies  with  routine 
screening could prevent the occurrence of most human cancers. In vivo imaging techniques have been 
developed  to  discover  small-size  tumours,  but  the  techniques  are  expensive.  Furthermore,  such 
imaging  techniques  cannot  distinguish  pre-cancerous  lesions  from  malignancies  very  well.  Even 
serologic tumour markers have limited sensitivity and specificity, with un-excepted high false positivity. 
Therefore, development of new techniques for discovery of pre-cancerous diseases is still needed [6]. 
Thymidine kinase (TK) activity in serum is a tumour growth-related marker which has been used 
for prognosis and monitoring of treatment of lymphoma and leukaemia since 1980 [7-10], and also to 
some extent in patients with solid tumours [9-11]. No immunohistology based on TK1 was available 
due  to  lack  of  useful  anti-TK1  antibodies.  However,  the  development  by  us  of  new  generations  
of  chicken  polyclonal  (IgY)  [12]  and  mouse  monoclonal  anti-TK1  antibodies  [13]  extended  the  
clinical  use  of  TK1  to  almost  all  types  of  solid  human  tumours,  for  both  serum  [12,14-27]  and 
immunohistology [12,13,28] analysis. With these anti-TK1 antibodies, TK1 protein concentration in 
serum (STK1) is now useful for prognosis [17,22,26,27], treatment monitoring [14,16,18,19,21-23], 
and discovery of recurrence [17-19,21,24] of various types of solid tumours, in addition to lymphoma 
and leukaemia, showing an increasingly important role of TK1 in the clinical setting. Serological TK1 
seems also to be useful for early screening of hyperplasia/neoplasia [1-3,15,19,20] and thus could be 
used as a warning system for development of malignancies later in life. 
In  this  study  we  investigated  the  use  of  a  sensitive  chemiluminescent  dot  blot  assay  for 
determination  of  STK1  as  a  biomarker  for  pre-malignancy/malignancy  in  health  screening.  We 
combined previously published health screening results [1-3] with new, extensive health screening data 
(n  =  7,080),  all  obtained  in  China  between  2005  to  2011,  involving  35,365  people  in  total.  We 
compared health conditions in relation to TK1 protein concentration in the serum of people living in 
large  and  moder  with  people  living  and  working  in  the  countryside,  where  industrial  pollutions  
(land-based oil field) probably influence health conditions in different ways compared to those of city 
dwellers. The TK1 serum assay is a commercial kit based on human TK1 chicken (IgY) antibodies 
produced  by  SSTK  Ltd.  (Shenzhen,  China).  These  TK1  antibodies  are  the  only  TK1  antibodies 
available today with a sensitivity and specificity high enough to discriminate between, one the one 
hand,  healthy  people  and  people  of  non-malignant  diseases,  and  on  the  other,  people  with  
pre-malignancies and malignancies. The present extensive study confirmed the results of the earlier 
studies, showing the usefulness of serological TK1 for health screening. 
2. Material and Methods 
2.1. Health Screening 
Health screening of 35,365 people was performed at the Health Centre and Medical Experimental 
Centre of the Third XiangYa Hospital, ZhongNan University, Changsha; at the Fujian Second Hospital Sensors 2011, 11  11067 
 
 
Health Centre, Fuzhou; and at the Health Exam Centre, General Hospital of Jilin Oil  Field, Jilin, 
China, 2005–2010 (Table 1). People undergoing the health screening test were covered by medical 
insurance, and represented people living in a large and modern city (population > 10 million) and 
people working at a land-based oil field. All participants were tested for STK1 in addition to three 
different  medical  test  protocols  routinely  used  at  these  health  centres:  (1)  blood  and  urine  tests;  
(2) imaging examination; and (3) physical examination. 
Table  1.  Characteristics  of  citydwellers  and  oilfield  workers  with  diseases  linked  to 
development of malignancies. The statistical calculations were done by  chi-square test.  
The star (*) indicates groups of statistically significant differences. 
Type  City  Oil field  X
2  DF  P-value 
Age (year) 
Normal STK1 
Elevated STK1 
 
41.2 ±  11.0 
43.8 ±  11.8 
40.7 ±  9.1 
41.0 ±  9.3  -  -  - 
Sex (man/woman, %) 
Normal STK1 
Elevated STK1 
 
59/41 
51/49 
86/14 
87/13  -  -  - 
Malignant  4/26,484 
(0.02%) 
1/8,869 
(0.01%) 
0.07  1  0.793 
* Pre-malignant,  
all types of moderate/severe degree 
6,926/26,484 
(26.2%) 
1,731/8,869 
(19.5%) 
98.60  1  <0.001 
* Refractory anaemia  303/26,484 
(1.1%) 
3,475/8,869 
(39.2%) 
7,072.80  1  <0.001 
* Benign  7,386/26,484 
(27.9%) 
2,169/8,869 
(24.5%) 
22.92  1  <0.001 
* Fatty liver  3,825/26,484 
(14.4%) 
2,840/8,69 
(32.0%) 
856.68  1  <0.001 
* Obesity  2,462/26,484 
(9.3%) 
1,470/8,869 
(16.6%) 
276.0  1  <0.001 
2.2. Cancer Patients 
Cancer  patients  (n  =  720)  with  11  different  types  of  malignant  tumours  were  enrolled  at  the 
Department of Clinical and Laboratory Medicine, Nanjing 81 Hospital, Jiangsu, China; the Department 
of Clinical and Laboratory Medicine, The Second Hospital Affiliated to Southeast University, Nanjing, 
China; the Department of Clinical and Laboratory Medicine, Zhejiang Cancer Hospital, Hangzhou, 
China;  the  Department  of  Clinical  Laboratory,  Chinese  Medicine  Hospital,  Guangdong  Province, 
China, and at the Central Laboratory, Cancer Institute & Hospital, CAMS, Beijing, China. 
2.3. Diagnosis 
Participants in the health screening were diagnosed for malignancies, pre-malignancies such as any 
types  of  polyploidy  lesions;  moderate/severe  hyperplasia  (mainly  breast  hyperplasia  or  prostate 
hyperplasia (proliferation tissue) detected by enlargement of the gland discovered by ultrasound and 
urination); moderate/severe cervical erosion; gastric ulcer; superficial atrophic gastritis and fatty liver; Sensors 2011, 11  11068 
 
 
refractory anaemia; other diseases, including benign lesions, overweight, anaemia (such as marrow 
infiltration and chronic disorders), hepatitis B virus (HBV), and chronic inflammations (Helicobacter 
pylori, papilloma virus, etc.) with abnormalities of blood and urine biochemical changes [29] that 
might link to the risk of development of pre-malignant/malignant diseases [29]. At the request of the 
health centres, participants were also tested for heart diseases (cardiac enlargement, coronary disease, 
arteriosclerosis,  myocardial  infarction,  irregular  heart  beat),  blood  pressure,  stones  (kidney,  gall 
bladder), and tuberculosis. 
2.4. Follow-Up 
Some  of  the  people  with  elevated  STK1  values  (170/702)  and  with  normal  STK1  values 
(6,354/26,484) were followed up between 5 and 72 months after the first STK1 test, regarding progress 
of pre-malignancies, appearance of new malignancies, and death. 
2.5. TK1 in Serum 
The  concentration  of  STK  was  measured  by  using  a  commercial  kit  based  on  an  enhanced 
chemiluminescent (ECL) dot blot assay (SSTK Ltd., Shenzhen, China). Samples comprising 3 µ L of 
serum  were  directly  applied  to  nitrocellulose  membrane.  The  serum  samples  were  probed  with  
anti-TK1 chicken IgY antibody raised against a peptide and the immunogen TK1 peptide was dotted at 
different concentrations (20, 6.6, and 2.2 pM) as an extrapolation standard. The intensities of the spots 
on the membrane were determined by a CCD camera (CIS-l Imaging System, SSTK Ltd., Shenzhen, 
China). From the intensities of the TK1 standard of known concentrations, the STK1 concentration 
was calculated and expressed as pM. The CV was less than 10%. The threshold value of STK1 was set 
to 2.0 pM. Participants with STK1 values of less than 2.0 pM were denoted as the normal STK1 group, 
considered low risk for developing malignancies. People with STK1 values ≥2.0 pM were denoted as 
the  elevated  STK1  group,  likely  representing  individuals  with  increasing  risk  of  pre-malignancy/ 
malignancy progression. 
2.6. Statistical Analysis 
The  mean  values  of  STK1  levels  were  calculated  by  a  mean  ±   standard  deviation  programme 
(Microsoft Excel). For comparison of STK1 concentration levels among the different groups of people 
investigated, Kruskal-Wallis and chi-square tests were used (Test-It, K). P-values ≤ 0.05 were regarded 
as  statistically  significant.  This  study  was  conducted  in  accordance  with  the  Helsinki  Declaration  
of 1983. 
3. Results 
3.1. STK1 Assay 
The  sensitivity  and  specificity  of  the  STK1  assay  were  determined  by  a  receiver  operation 
characteristic  (ROC)  analysis. Cancer patients (n =  720)  with 11 different types of tumours were 
compared to healthy people and people with various illness (n = 4,103) except for pre-malignancies or 
malignancies (Table 2, Figure 1).  Sensors 2011, 11  11069 
 
 
Table 2. Receiver operation characteristic (ROC) characterization of patients (n = 720) 
with various types of tumours in relation to healthy people and people with different types 
of illnesses (total n = 4,103), except for people with pre-malignant and malignant diseases. 
Type  ROC-value  SE  Z  p  Sensitivity  Specificity  Likelihood (+)  n 
All tumors  0.96  0.005  92.77  <0.001  0.798  0.997  233.73  720 
Liver  0.98  0.009  51.78  <0.001  0.857  0.997  251.69  35 
Cervical  0.96  0.016  29.58  <0.001  0.689  0.997  199.68  25 
Ovari  0.95  0.045  10.12  <0.001  0.857  0.997  251.69  7 
Lung  0.96  0.009  50.07  <0.001  0.729  0.997  214.11  192 
Breast  0.94  0.005  100.96  <0.001  0.943  0.997  277.02  53 
Esophagus  0.95  0.012  37.82  <0.001  0.757  0.997  222.39  136 
Gastric  0.92  0.033  12.68  <0.001  0.706  0.997  207.28  34 
Other degistive  0.96  0.026  17.91  <0.001  0.692  0.997  203.29  13 
Thyroid  0.94  0.019  22.86  <0.001  0.873  0.997  256.22  102 
Head&Neck  0.97  0.012  37.81  <0.001  0.817  0.997  239.93  82 
Lymphoma  1  0.002  301.92  <0.001  0.971  0.997  285.25  35 
Others  1  0.001  807.09  <0.001  1  0.997  293.64  6 
Figure 1. Receiver operation characteristic (ROC) analysis of the chemiluminescent dot 
blot assay of 720 cancer patients with 11 different types of tumours and of 4,103 healthy 
people and people with different types of illnesses, except for individuals with pre-malignant 
or malignant diseases. The ROC value is 0.96. See Table 2 for statistical details. 
 
The mean ROC value, including all type of cancer patients (n = 720), was 0.96. The ROC values 
among the different tumour types varied between 0.92 and 1.0. The sensitivity and the specificity at an 
STK1 cut-off value of 2.0 pM (used in this health screening study) based on all types of tumours  
were 0.798 and 0.997, respectively, with a likelihood (+) value of 233.73. Decreasing the STK1 cut-off 
value  down  to  1.5  pM  increased  the  sensitivity  to  0.86,  but  reduced  the  specificity  to  0.95  (data  
not shown). Sensors 2011, 11  11070 
 
 
3.2. Number of People with Elevated STK1 Values 
The  relative  number  of  city-dwelling  people  with  elevated  STK1  values  (≥2.0  pM)  was  0.8%  
(n = 198/26,484), while the corresponding value for the oil-field workers was 5.8% (n = 514/8,869). 
Furthermore, the number of people working in oidrilling/oil transportation was statistically significantly 
higher (7.8%), compared to people working in the oil-field service/office (3.9%) (Table 3). 
Table  3.  Number  of  persons  with  elevated  STK1  values  working  in  oil  drill/oil 
transportation  or  of  persons  working  in  oil-field  service/office.  The  statistical  
calculations were done by Chi-square test. The stars (*) indicate groups of statistically  
significant differences. 
Type 
Oil production/ 
transportation 
Oil field 
service/office  X
2  DF  P-value 
STK1 
 
338/4,333 
(7.8%) 
176/4,536 
(3.9%) 
55,53  1  <0.0001 
Malignant 
 
0/338 
(0%) 
1/176 
(0.6%) 
1.91  1  0.167 
* Pre-malignant,  
all types of moderate/severe degree 
56/338 
(16.6%) 
16/176 
(9.1%) 
4.14  1  0.042 
Refractory anaemia  150/338 
(44.4%) 
72/176 
(40.9%) 
0.23  1  0.634 
* Benign  40/338 
(11.8%) 
10/176 
(5.7%) 
4.18  1  0.041 
Fatty liver  71/338 
(21.0%) 
34/176 
(19.3%) 
0.13  1  0.714 
Obesity  98/338 
(29.0%) 
46/176 
(26.1%) 
0.27 
 
1  0.606 
3.3. Pre-Malignant and Malignant Diseases of Normal and Elevated STK1 Groups  
Participants were subdivided into 14 groups, depending on diseases or health conditions (Tables 4 
and 5). In about 15 percent of participants the number of cases was higher than the number of people, 
had more than one type of disease (data not shown, see [1,3]). 
3.3.1. City-Dwelling People 
In the normal STK1 group of city-dwelling people (Table 4), the largest number of people were 
found in the subgroup of low-risk diseases (46.1%), followed by the subgroups for benign (27.8%), 
pre-malignancies of all types (25.9%), hyperplasia (22.4%, breast or prostate hyperplasia), mild and 
moderate/severe types of fatty liver (22.1% and 14.5%, respectively), obesity (9.3%), and high-risk for 
HBV (6.7%). No people with malignancies were found in the normal STK1 group of city-dwelling 
group. Only 2.0% were regarded as disease- and illness-free. The mean STK1 values of the normal 
STK1 group were less than 1.0 pM (0.3–0.8 pM). Sensors 2011, 11  11071 
 
 
Table  4.  Number of city-dwelling people of the normal and elevated STK1 groups of 
various diseases. The malignancies in the elevated STK1 group were of early tumour stage. 
The  low-risk  diseases  consist  of  HBV  score  types  2,  4,  5  or  2,  5;  mild  degree  of 
hyperplasia; cervical erosion; gastric ulcer; and fatty liver of low risk. The illness-free 
group was defined as no detectable diseases or illness. The statistical calculations were 
done by chi-square test. The stars (*) indicate groups of statistically significant differences. 
Type 
Normal 
STK1 group 
Elevated 
STK1 group  X
2  DF  P-value 
Number of people 
* Malignant 
26,484 
0/26,286 
(0%) 
198 
4/198 
(2.0%) 
 
520.60 
 
1 
 
<0.001 
* Pre-malignant, all types of 
moderate/severe degree 
6,801/26,286 
(25.9%) 
125/198 
(63.1%) 
67.25  1  <0.001 
Breast, lobular hyperplasia,  
mild type 
474/12,823 
(3.7%) 
1/108 
(0.9%) 
2.27  1  0.137 
* Breast, lobular hyperplasia, 
moderate/severe type 
3,109/12,823 
(24.2%) 
53/108 
(49.1%) 
18.14  1  <0.001 
Prostate hyperplasia,  
mild type 
916/15,543 
(5.9%) 
5/90 
(5.6%) 
0.02  1  0.898 
* Prostate hyperplasia,  
moderate/severe type 
1,380/15,543 
(8.9%) 
26/90 
(28.9%) 
30.94  1  <0.001 
* Refractory anaemia  268/26,286 
(1.0%) 
35/198 
(17.7%) 
405.50  1  <0.001 
Benign  7,318/26,286 
(27.8%) 
68/198 
(34.3%) 
2.22  1  0.163 
* HBV high risk,  
1, 3, 5 or 1, 4, 5 types 
1,760/26,286 
(6.7%) 
23/198 
(11.6%) 
6,33  1  0.012 
* Fatty liver, mild type  2,268/10,283 
(22.1%) 
8/78 
(10.3%) 
4.45  1  0.035 
Fatty liver,  
moderate/severe type 
3,808/26,286 
(14.5%) 
17/198 
(8.6%) 
0.24  1  0.622 
Obesity  2,448/26,286 
(9.3%) 
14/198 
(7.1%) 
0.99  1  0.319 
* Low risk diseases  12,105/26,286 
(46.1%) 
29/198 
(14.6%) 
36,84  1  <0.001 
* Illness-free  519/26,286 
(2.0%) 
0/198 
(0%) 
3.91  1  0.048 
 
In the elevated STK1 group of the city-dwelling people (Table 4) a significantly higher number of 
people were found, as compared to people of the normal STK1 group, in the following: malignancy 
(2.0% versus 0%), pre-malignancies of all types (63.1% versus 25.9%), breast lobular hyperplasia of 
moderate/severe  type  (49.1%  versus  24.2%),  prostate  hyperplasia  (28.9%  versus  8.9%),  refractory 
anaemia (17.7% versus 1.0%), and high-risk for HBV (11.6% versus 6.7%). A significantly lower 
number of people was found among those with mild type of fatty liver (10.3% versus 22.1%), low-risk Sensors 2011, 11  11072 
 
 
diseases (14.6% versus 46.1%), and illness-free (0% versus 2%). No significant difference was found 
among  people  with  benign,  fatty  liver  of  moderate/severe  type,  and  obesity.  Thus,  there  was  a 
significantly higher frequency (85.4%) of diseases linked to pre-malignancy and malignancy in the 
group of elevated STK1 value, compared to the normal STK1 group (52.4%) (Table 5). 
 
Table 5. The frequency of pre-cancer diseases of different types (see Tables 4 and 5) of the 
STK1 normal and elevated groups of people living in a city or oil field. The statistical 
calculations were done by chi-square test. 
Type  Pre-cancer diseases  X
2  DF  P 
City         
Normal  52.4%       
Elevated  85.4%  21.9  1  <0.001 
Oil field         
Normal  57.8%       
Elevated  85.2%  35.2  1  <0.001 
 
The mean STK1 values of the various subgroups of the elevated STK1 group were significantly 
higher than the corresponding STK1 values of the normal STK1 group, in the range of 3.3 to 4.0 pM  
(p < 0.001). 
 
3.3.2. Oil-Field Workers 
 
The relative number of people working at the oil-field production company with elevated STK1 
values (>2.0 pM) was 5.8%, much higher compared to the city-dwelling people (0.8%). This may 
reflect the significantly higher frequency of people with refractory anaemia found among the oil-field 
workers (39.2%), compared to the city dwellers (1.1%) (Table 1). The number of people working at 
the oil-field company with elevated STK1 values showing fatty liver or obesity was also significantly 
higher compared to the city-living people with elevated STK1 values (fatty liver 32.0% versus 14.4%; 
obesity 16.6% versus 9.3%) (Table 1). Thus, the differences in the frequency of the various diseases 
between the oil-field workers and city dwellers may reflect differences in living conditions. 
In the normal STK1 group the highest number of people was found in the subgroup of low-risk 
diseases  (40.7%),  followed  by  refractory  anaemia  (37.9%),  fatty  liver  of  moderate/high  risk,  
benign (24.7%), pre-malignancies of all types (19.1%), HBV of high risk (19.0%), and obesity (16.2%) 
(Table 6). No participants with mild type of fatty liver were reported, nor people with breast or prostate 
hyperplasia  (Table  6).  The  mean  STK1  values  of  the  normal  STK1  group  were  less  than  1.0  pM  
(0.7–0.9 pM). Sensors 2011, 11  11073 
 
 
Table 6. Number of oil-field work ers of the normal and elevated STK1 groups by various 
diseases.  The  malignancy  in  the  elevated  STK1  group  was  of  early  tumour  stage.  The  
low-risk diseases consist of HBV score types 2, 4, 5 or 2, 5; mild degree of hyperplasia; 
cervical erosion; gastric ulcer; and fatty liver of low risk. The illness-free group was defined 
as no detectable diseases or illness. The statistical calculations were done by chi-square test. 
The stars (*) indicate groups of statistically significant differences. (-) = no data. 
Type 
Normal 
STK1 group 
Elevated 
STK1 group  X
2  DF  P-value 
Number of persons 
* Malignant 
8,355 
0/8,355 
(0%) 
514 
1/514 
(0.2%) 
 
16.23 
 
1 
 
<0.001 
* Pre-malignant, all types of 
moderate/severe degree 
1,599/8,355 
(19.1%) 
132/514 
(25.6%) 
8.48  1  0.004 
Breast lobular hyperplasia,  
mild type  -  -  -  -  - 
Breast lobular hyperplasia, 
moderate/severe type  -  -  -  -  - 
Prostate hyperplasia, mild type  -  -  -  -  - 
Prostate hyperplasia,  
moderate/severe type 
-  -  -  -  - 
Refractory anaemia  3,163/8,355 
(37.9%) 
220/514 
(42.8%) 
2.18  1  0.140 
* Benign  2,067/8,355 
(24.7%) 
102/514 
(19.8%) 
3.95  1  0.047 
HBV high risk,  
3, 5 or 1, 4, 5 types 
1,586/8,355 
(19.0%) 
93/514 
(18.1%) 
0.17  1  0.679 
Fatty liver, mild type  -  -  -  -  - 
* Fatty liver,  
moderate/severe type 
2,739/8,355 
(32.9%) 
101/514 
(19.6%) 
21.67  1  <0.001 
* Obesity  1,355/8,355 
(16.2%) 
115/514 
(22.4%) 
0.99  1  0.003 
* Low risk diseases  3,399/8,355  
(40.7%) 
76/514 
(14.8%) 
71.43  1  <0.001 
* Illness-free  124/8,355 
(1.5%) 
0/514 
(0%) 
7.62  1  <0.001 
 
When comparing the  elevated STK1 group with the normal STK1 group, a significantly higher 
number of people were found with pre-malignancies of all type (25.6% versus 19.1%) and with obesity 
(22.4% versus 16.2%) (Table 6). A significantly reduced number of cases were found among people 
with benign tumours (19.8% versus 24.7%), fatty liver of moderate/severe type (19.6% versus 32.9%), 
and low-risk diseases (14.8% versus 40.7%) (Table 6). No differences among people with HBV of 
high risk or refractory anaemia were seen between people with normal and elevated STK1 values 
(Table 6). The number of illness-free participants was 1.5% (Table 6). The mean STK1 values of the 
normal STK1 group were less than 1.0 pM (0.3–0.8 pM). There was a significantly higher frequency Sensors 2011, 11  11074 
 
 
(85.2%)  of  diseases  linked  to  pre-malignancies  and  malignancies  in  the  elevated  STK1  group, 
compared  to  the  normal  STK1  group  (57.8%)  (Table  6).  The  mean  STK1  values  of  the  various 
subgroups of the elevated STK1 group were significantly higher than the corresponding STK1 values 
of the normal STK1 group, in the range of 2.8 to 4.3 pM (p < 0.001). 
3.4. Follow-Up 
In  the  elevated  STK1  group  some  of  the  people  were  followed  up  (170/702)  between  5  
and 72 months. Ten people (5.9%) developed new malignancies (carcinoma of gastric, liver, ovary, 
prostate) within 72 months and three people (1.8%) died in their cancer diseases (carcinoma of gastric 
and liver) within 43 months (Table 7). Of the people that died, one had malignancy at the time for the 
first health screening, and the other two developed new tumours later. Five people (2.9%) showed 
progress in their pre-malignancy diseases up to 72 months (breast and prostate hyperplasia, HBV of 
high risk) (Table 7), while 23 showed no further progress up to 72 months (data not shown). Five 
people received treatment for their diseases (surgery, chemotherapy, HBV treatment) (Table 7). Thus, 
of  the  people  with  elevated  STK1  values,  five  people  showed  progress  in  their pre-malignancies,  
10 people developed new malignancies, and three people died in cancer disease. This is in the range of 
new cancer cases of 8.8–21.8% reported of women with breast hyperplasia showing higher risk of 
developing  breast  malignancy,  especially  among  women  with  adenoid  gland  disease  and  breast 
malignancy in their family history [30].  
Table 7. Follow-up of the STK1 elevated group (170/702) and the STK1 normal group 
(6,354/26,484). The follow-up time was 5 to 72 months. 
Type  Number of patients  Notes 
STK1 Elevated Group     
New malignancies  10  Gastric carcinoma, liver 
carcinomas, ovarian carcinoma, 
prostate carcinoma. 
Death 
 
 
Progressed pre-malignancy 
3 
 
 
5 
One gastric carcinoma, died after 
17 months; two liver carcinomas, 
died after 11 and 43 months. 
Hyperplasia of breast and prostate, 
high risk HBV. 
Patients in tumour treatment  5  Surgery, chemotherapy, HBV 
treatment, change of life style. 
STK1 Normal Group     
New malignancies 
 
 
 
Death 
Progressed pre-malignancy 
Patients in tumour treatment 
2 
 
 
 
0 
0 
2 
One liver carcinomas diagnosed 
and operated after 60 months; one 
breast carcinoma diagnosed and 
operated after 60 months. 
 
 
Surgery 
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Furthermore,  a  cancer  incidence  rate  of  0.2%–0.3%  found  in  China  [31]  should  give  an 
accumulated number of new malignant cases of 2–3 people during six years in the elevated STK1 
group.  However,  10  people  with  new  malignancies  were  found  in  this  group.  Thus,  there  is  a 
statistically significant increased risk of about three to five times to develop new malignancies in the 
elevated STK1 group compared to the normal cancer incidence rate (2/170 versus 10/170; X
2 = 5.15, 
DF = 1, p = 0.023, 3/170 versus 10/170; X
2 = 3.63, DF = 1, p = 0.057). 
In the normal STK1 group, some of the participants (6,354/26,484) were followed up to 72 months 
(Table 7). Those people were subdivided into three groups and followed for 48 months (n = 2,587),  
60 months (n = 2,713), and 72 months (n = 1,054), respectively. No new malignancies were found in 
group one (48 months) or group two (60 months), but two new cases (liver and breast carcinoma) were 
found in group three (72 months). Those people were treated by surgery. No people in the normal 
STK1 group showed further progress in their pre-malignancies or died. Thus, in the normal STK1 
group 0.2% (2/1,054) developed new malignancies within six years. This is statistically significantly 
lower compared to the number of new malignant cases found in the elevated STK1 group (10/170 
versus 2/1,054; X
2 = 78.36, DF = 1, p < 0.001). 
3.5. Age Distribution 
There was no significant difference in the age distributions between the elevated and the normal 
STK1 groups or between the other subgroups studied (data not shown). 
4. Discussion 
TK1  is  an  enzyme  linked  to  DNA  synthesis,  and  thus  expressed  in  proliferating  cells,  both  
non-malignant and malignant. The concentration and activity of TK1 in blood serum of cancer patients 
are elevated, while TK1 in serum of healthy people is low or undetectable [10,12,32]. However, in 
some healthy people showing acute illness (infection, inflammation) or exhibiting other physiological 
changes (menstruation, blood donor, surgery), TK1 could increase transiently. The reason(s) behind 
the differences in the STK1 levels of healthy people and people with malignancies are still not fully 
understood. One possible explanation is linked to cell death. It is known that normal, non-malignant 
cells die in G1/G0 of the cell cycle, where the intracellular concentration of TK1 is low, while tumour 
cells die also in S/G2 stage of the cell cycle, where TK1 concentration is high [10,32], generating more 
TK1 in serum. It is also possible that a factor in serum affects the stability of TK1 in serum, acting 
differently in healthy people compared to cancer patients [15]. However, it cannot be excluded that 
TK1 is excreted from living normal and tumour cells in different ways. Since TK1 in serum shows 
transient increases when people have infection/inflammation due to activation of the immune system, 
it cannot be excluded that at least part of the elevated TK1 concentration in the serum of cancer 
patients is a result of a stimulated immune system and is not only excreted from tumour cells. Thus, 
when judging the implication of an elevated STK1 value as a risk of development of malignancies, 
reasons for the transient elevated STK1 values other than potential malignancies should also be taken 
in account [10]. Therefore, access to medical histories of patients is of importance. Sensors 2011, 11  11076 
 
 
The  present  health  screening  study  of  more  than  35,000  people  shows  that  TK1  protein 
concentration in serum (STK1) could be a useful biomarker for detection of people at the risk to 
develop  malignancies  later  in  life.  The  STK1  assay  used  is  able  to  discriminate  between  tumour 
patients and healthy people, and people with various illnesses/non-malignant proliferation diseases 
(ROC value 0.96, likelihood (+) 233.73, sensitivity 0.798, specificity 0.997). The number of false-positive 
cases is low (1/300) compared to other biomarkers in use today, for example, mammography and PSA. 
Thus, the high ROC and likelihood (+) value show that the STK1 assay meets the requirements of a 
health  screening  test.  Furthermore,  since  most  malignant  patients  (65–90%)  express  an  STK1 
concentration >2.0 pM [15], it is reasonable to suspect that people with STK1 values >2.0 pM, but still 
not showing visible tumours, have an increased risk to develop malignancies later in life. On the other 
hand, people with STK1 values <2.0 pM likely have a lower risk to develop malignancies. We suggest 
that  people  with  STK1  values  >2.0  pM  should  recheck  their  STK1  values  and  health  conditions  
within 3–6 months, while people with STK1 values <2.0 pM have their annual health test. 
We found that the frequency of STK1 values varied, depending on living conditions, that is, 0.8% 
of the city dwellers and 5.8% of the land-based oil-field workers. Both these values are higher than the 
cancer incidence rate of China today (0.2–0.3%) [31]. A cancer incidence rate is based on the whole 
population, but could differ in subgroups of people, depending on living conditions. It is possible that 
those people living and working in an oil-field area are exposed to pollut that lead to higher frequency 
of proliferation-related diseases, such as pre-malignancy/malignancy. The significantly different STK1 
values found in this study between the oil drilling/oil transportation staff and the people working in the 
oil company service/office suggest that the working conditions for the people participating in this 
study affect the frequency of malignancy-related diseases, and as a consequence, the STK1 values. It 
should also be noted that about 85% of the people in the STK1 elevated group are pre-malignant cases. 
However, not all pre-malignant cases ended up in malignancies. For example, only about 10–20% of 
women with pre-malignant breast hyperplasia show a higher risk of developing breast malignancy [30]. 
In the present study, about 95% of the breast hyperplasia was of lobular type, in accordance with a 
Chinese study of women showing about 83% of breast adenoids of lobular hyperplasia type [33]. 
Lobular neoplasia broadly defines the spectrum of changes within the lobule, ranging from atypical 
lobular hyperplasia (ALH) to lobular carcinoma in situ (LCIS). These types of lesions are associated 
with an increased risk for developing subsequent invasive breast cancer [34-36]. Thus, if the STK1 
value  is correlated to  pre-malignant diseases, the  frequency of people with  elevated STK1 values 
should be higher than the cancer incidence rate. 
The number of people with malignancies in this study was about 30 times less than expected from 
the  cancer  incidence  rate  of  China  (0.01%  versus  expected  0.2–0.3%)  [31].  However,  those  with 
malignancies were exclusively found in the group of people with elevated STK1 values, indicating that 
the  cut-off  value  of  STK1  2.0  pM  is  useful  for  identifying  people  with  malignancies  in  health 
screening. The reason for the limited number of people with malignancies found is that people who 
participate in health screening regard themselves as healthy, with no obvious symptoms. In China 
today, those with obvious symptoms for malignancies (pain, reduced weight, blood in urine/faeces, 
fever, etc.) contact the hospital directly. 
A more interesting subject is how many people with elevated STK1 will develop malignancies later 
in life. Since the development of malignancies from pre-malignancies takes rather a long time, such Sensors 2011, 11  11077 
 
 
studies need 10–15 years follow-up. In this study we were able to follow some of the people (24%) of 
the elevated STK group for six years. We found that there was about 30 times higher risk to develop 
new malignancies in the elevated STK1 group compared to the normal STK1 group. 
The  elevated  STK1  value  also  correlated  to  moderate/severe  type  of  hyperplasia of  breast  and 
prostate, but not to low-risk hyperplasia. No such correlation was found in people with HBV and fatty 
liver of moderate/high risk, or to with obesity. This further supports the notion that STK1 specifically 
reflects changes in proliferation of pre-malignancies, but not of pre-malignancies that do not yet show 
uncontrolled  proliferation,  indicating  the  proliferation  specificity  of  TK1  in  serum.  This  is  in 
accordance with the observation that women with breast hyperplasia show a high risk of developing 
breast malignancy [30]. 
The  higher  frequency  of  breast  and  prostate  hyperplasia  found  among  city-dwelling  people 
compared to those living in the countryside is in accordance with previous reports. The frequency of 
breast  and  prostate  hyperplasia  is  increasing  in  city  residents  of  China.  The  frequency  of  breast 
hyperplasia is now 30–50% of women aged around 40 years [30], and 18% of men with prostate 
hyperplasia [37]. On the other hand, only 2.1% of women living in the countryside in China show 
breast hyperplasia [38]. Although the significance of prostate benign hyperplasia (PBH) and atypical 
adenoma hyperplasia (AAH) for the development of prostate carcinoma is still debated, there seems to 
be a link to progression of malignancy [39-43].  
Obesity  is  now  considered  to  be  a  multifunctional  chronic  disease,  resulting  from  interactions 
between genetic and environmental factors [44]. Obesity is a significantly increased risk factor of 
mortality in cancer and accounts for about 20% of the more frequent type of malignancies [45]. In an 
epidemiological investigation of 401,215 participants [46], an increased risk of mortality in cancer 
between 1.50 and 4.21 times was found, depending on the type of malignancy.  
5. Conclusions 
This study indicates that the chemiluminescent dot blot STK1 assay can distinguish between people 
with low or high risk of developing malignancies, before any indication of visible tumours. Hence, 
TK1  in  serum  is  useful  in  health  screening  as  a  reliable  tumour-proliferating  marker  alone  or  in 
combination with routine inspections for an early risk warning assessment of malignant process. The 
STK1  assay  can  be  applied  to  different  occupations  and  groups,  particularly  in  cancer  frequency  
high-risk areas such as industries with chemical exposures, and among elderly people.  STK1 is a 
reliable marker for assessment of tumour cell proliferation that can achieve the goal of “early detection 
and early treatment of tumours”. 
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